BIOMAT Database Logo BIOMAT Database Logo

Brompheniramine maleate: a double-blind, placebo-controlled comparison with terfenadine for symptoms of allergic rhinitis. 1998

W R Thoden, and H M Druce, and S A Furey, and E A Lockhart, and P Ratner, and F C Hampel, and J van Bavel
Department of Clinical Research, Whitehall-Robins Healthcare, Madison, NJ 07940, USA.

This was a double-blind, randomized, placebo-controlled, multicenter, parallel study comparing the effectiveness, at recommended doses, of an extended-release formulation of brompheniramine maleate and terfenadine in the treatment of allergic rhinitis. Subjects with symptoms of seasonal and/or perennial allergic rhinitis received brompheniramine 12 mg (n = 106), 8 mg (n = 105), terfenadine 60 mg (n = 106), or placebo (n = 53) twice daily for 14 days. On treatment days 3, 7, and 14, symptom severity ratings (i.e., rhinorrhea, sneezing, nasal congestion, itchy nose, eyes or throat, excessive tearing, postnasal drip) were completed by the physician; subjects and physicians each completed a global efficacy evaluation. Brompheniramine 12 mg and 8 mg and terfenadine were more effective than placebo (p < or = 0.05) on the physicians' global: brompheniramine 12 mg was more effective than terfenadine (p < or = 0.05) on days 7 and 14 and brompheniramine 8 mg on day 3. On the subjects' global evaluation, brompheniramine 12 mg and 8 mg and terfenadine were more effective than placebo (p < or = 0.05); brompheniramine 12 mg was more effective than terfenadine (p < or = 0.05) on days 7 and 14 and brompheniramine 8 mg on day 3. In general, brompheniramine 8 mg was comparable to terfenadine. On days 3 and 7, the total symptom and total nasal symptom severity scores for subjects receiving brompheniramine 12 mg were significantly more improved than for placebo (p < 0.05); terfenadine was not different from placebo; brompheniramine 12 mg was significantly better than terfenadine on day 7 (p < 0.05) for reducing total symptom severity and on days 3, 7, and 14 for reducing total nasal symptom severity. Adverse experiences were reported by 155 (41.9%) of the 370 subjects enrolled in the study. The overall rate of adverse experiences in the brompheniramine 12 mg treatment group (57.5%) was significantly greater (p < 0.05) than for brompheniramine 8 mg (38.1%), terfenadine (31.1%), and placebo (39.6%). In conclusion, an extended-release formulation of brompheniramine 12 mg or 8 mg bid alleviates allergic rhinitis symptoms and brompheniramine 12 mg provides significantly better relief of these symptoms than terfenadine 60 mg bid.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001977 Brompheniramine Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. p-Bromdylamine,para-Bromdylamine,Brompheniramine Maleate,Brompheniramine Maleate (1:1),Chlorphed,Dimetane,Dimetane-Ten,Dimetapp Allergy,Oraminic-2,Dimetane Ten,Maleate, Brompheniramine,Oraminic 2,p Bromdylamine,para Bromdylamine
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006255 Rhinitis, Allergic, Seasonal Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS. Hay Fever,Pollen Allergy,Pollinosis,Seasonal Allergic Rhinitis,Hayfever,Allergic Rhinitides, Seasonal,Allergic Rhinitis, Seasonal,Allergies, Pollen,Allergy, Pollen,Fever, Hay,Pollen Allergies,Pollinoses,Rhinitides, Seasonal Allergic,Rhinitis, Seasonal Allergic,Seasonal Allergic Rhinitides
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

W R Thoden, and H M Druce, and S A Furey, and E A Lockhart, and P Ratner, and F C Hampel, and J van Bavel
Brompheniramine, terfenadine, and placebo in allergic rhinitis.
November 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
W R Thoden, and H M Druce, and S A Furey, and E A Lockhart, and P Ratner, and F C Hampel, and J van Bavel
Multicenter, double-blind, placebo-controlled trial of terfenadine in seasonal allergic rhinitis and conjunctivitis.
June 1985, Annals of allergy,
W R Thoden, and H M Druce, and S A Furey, and E A Lockhart, and P Ratner, and F C Hampel, and J van Bavel
Loratadine/pseudoephedrine for nasal symptoms in seasonal allergic rhinitis: a double-blind, placebo-controlled study.
April 2000, Ear, nose, & throat journal,
W R Thoden, and H M Druce, and S A Furey, and E A Lockhart, and P Ratner, and F C Hampel, and J van Bavel
Multicentre, double-blind comparison of terfenadine and cetirizine in patients with seasonal allergic rhinitis.
March 1990, The British journal of clinical practice,
W R Thoden, and H M Druce, and S A Furey, and E A Lockhart, and P Ratner, and F C Hampel, and J van Bavel
Multicenter, double-blind, placebo-controlled trial of terfenadine suspension in the treatment of fall-allergic rhinitis in children.
July 1986, The Journal of allergy and clinical immunology,
W R Thoden, and H M Druce, and S A Furey, and E A Lockhart, and P Ratner, and F C Hampel, and J van Bavel
Antihistaminic treatment of allergic rhinitis: a double-blind study with terfenadine versus dexchlorpheniramine.
January 1987, Pharmatherapeutica,
W R Thoden, and H M Druce, and S A Furey, and E A Lockhart, and P Ratner, and F C Hampel, and J van Bavel
The Effect of Levagen+ (Palmitoylethanolamide) Supplementation on Symptoms of Allergic Rhinitis-A Double-Blind Placebo-Controlled Trial.
November 2023, Nutrients,
W R Thoden, and H M Druce, and S A Furey, and E A Lockhart, and P Ratner, and F C Hampel, and J van Bavel
Terfenadine and brompheniramine maleate in urticaria and dermographism.
January 1986, Dermatologica,
W R Thoden, and H M Druce, and S A Furey, and E A Lockhart, and P Ratner, and F C Hampel, and J van Bavel
Double-Blind Placebo-Controlled Trial of Bepotastine Salicylate in Patients With Allergic Rhinitis.
March 2021, The Laryngoscope,
W R Thoden, and H M Druce, and S A Furey, and E A Lockhart, and P Ratner, and F C Hampel, and J van Bavel
Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis.
December 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
Copied contents to your clipboard!